Iovance Biotherapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 29, 2026, 5 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedIovance Biotherapeutics Reports Updated IOV-LUN-202 Non-Squamous mNSCLC Data: 24.6% ORR in 69 Patients, Biomarker-Enriched Subgroup at 59.1% ORR
8-KOct. 5, 2026, 5 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KSept. 29, 2026, 7:05 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 6, 2026, 5:30 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 6, 2026, 7:05 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits